Market Intelligence, Clinical Progress, and High-Purity Reagents for Mitochondrial Fission-Targeted Therapeutics.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for DRP1/DNM1L drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | DRP1/DNM1L Recombinant Protein High purity (>95%), Endotoxin controlled. Sequence Verified. Suitable for GTPase biochemical assays. |
View DRP1 Products |
| Gene Delivery | DRP1/DNM1L Promise-ORF / Lentivirus Full-length ORF for stable cell lines and mitochondrial morphology visualization. |
View DRP1 Products |
| Benchmark Ab | Anti-DRP1/DNM1L Recombinant Antibody Recombinant positive control for Western Blot, IHC, and Immunofluorescence. |
View DRP1 Products |
| Validator | DRP1/DNM1L siRNA Set For knockdown verification in mitochondrial dynamics assays. |
View DRP1 Products |
| Related Target A | MFF (Mitochondrial Fission Factor) Outer mitochondrial membrane receptor essential for DRP1 recruitment. |
View MFF Products |
| Related Target B | FIS1 (Mitochondrial Fission 1) Adapter protein mediating DRP1-induced mitochondrial fragmentation under stress. |
View FIS1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Selectivity over Dynamin-1/2/3 | High-purity DRP1 and Dynamin family proteins available for off-target counter-screening. |
| Protein Aggregation & Stability | Strictly monitored monomeric/oligomeric states verified by SEC-HPLC; endotoxin <1.0 EU/μg. |
| Lack of Controls | Highly characterized sequence-verified benchmark antibodies included for assay standardization. |
| False Positives | Validated siRNA pools included to confirm target-specific phenotypic rescue in cell-based assays. |
Live DRP1/DNM1L R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of DRP1 (Dynamin-1-like protein, DNM1L) is gaining significant traction across neurodegenerative, cardiovascular, and oncology pipelines. As a cytosolic GTPase responsible for mitochondrial outer membrane fission, aberrant DRP1 activation drives mitochondrial fragmentation, leading to neuronal death in Alzheimer's and Parkinson's diseases, and promoting chemoresistance in metabolic-rewired solid tumors.
The race for DRP1 therapeutics is intensifying, with major players shifting focus from traditional non-selective small molecules to highly selective allosteric inhibitors and peptide-based disruptors of DRP1-receptor interactions (e.g., DRP1-Fis1 or DRP1-Mff). As first-generation therapies reach preclinical validation, the next wave of R&D is targeting tissue-specific delivery and isoform-selective modulation to minimize systemic toxicities associated with basal mitochondrial fission.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Allosteric) | Academic Spin-offs, Biotech | Alzheimer's, Parkinson's, ALS | GTPase Activity Assay (Need highly active, non-aggregated recombinant DRP1 protein) |
| Peptide Inhibitors (P110-like) | Preclinical Biopharma | Myocardial Ischemia, Stroke | Protein-Protein Interaction (PPI) Assay (Need DRP1, MFF, and FIS1 binding panels) |
| Gene Therapy (RNAi/AAV) | Gene Therapy Specialists | Ophthalmic Diseases, Rare Neuropathies | Target Knockdown Validation (Need validated siRNA and Lentivirus for cell-line construction) |